{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:50:16Z","timestamp":1788814216199,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jhepr.2023.100751","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T02:22:24Z","timestamp":1680834144000},"page":"100751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-4147","authenticated-orcid":false,"given":"Mathias","family":"Jachs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Panzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3398-6120","authenticated-orcid":false,"given":"Lukas","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2587-1385","authenticated-orcid":false,"given":"Michael","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-3061","authenticated-orcid":false,"given":"Lorenz","family":"Balcar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-5786","authenticated-orcid":false,"given":"Jeremy V.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Munda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Mandorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan W.","family":"Aberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Zoller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-1992","authenticated-orcid":false,"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100751_bib1","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhepr.2023.100751_bib2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/ueg2.12163","article-title":"Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis","volume":"9","author":"Jachs","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhepr.2023.100751_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100751_bib4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100751_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2023.100751_bib6","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2023.100751_bib7","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFN\u03b1 for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100751_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2023.100751_bib9","unstructured":"European Medicines Agency. Hepcludex \u2013 summary of product characteristics https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex. Accessed 03 December\u00a02022."},{"key":"10.1016\/j.jhepr.2023.100751_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jhep.2022.03.004","article-title":"Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV\/HDV-associated compensated cirrhosis","volume":"77","author":"Schwarz","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100751_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a \u201creal world\u201d study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2023.100751_bib12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jvh.12175","article-title":"Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-\/HBV-coinfected patients","volume":"21","author":"Strassl","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2023.100751_bib13","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1128\/JCM.43.5.2363-2369.2005","article-title":"Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients","volume":"43","author":"Le Gal","year":"2005","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhepr.2023.100751_bib14","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.29574","article-title":"Genetic diversity and worldwide distribution of the deltavirus genus: a study of 2,152 clinical strains","volume":"66","author":"Le Gal","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100751_bib15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","volume":"75","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100751_bib16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2021.10.012","article-title":"Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis","volume":"76","author":"Loglio","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100751_bib17","article-title":"Measurement of the hepatic venous pressure gradient and transjugular liver biopsy","author":"Reiberger","year":"2020","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.jhepr.2023.100751_bib18","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/j.1572-0241.2005.50006_10.x","article-title":"Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a","volume":"100","author":"Ferenci","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2023.100751_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-109-2-95","article-title":"Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial","volume":"109","author":"Perrillo","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2023.100751_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199008023230503","article-title":"A\u00a0randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group","volume":"323","author":"Perrillo","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100751_bib21","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2023.100751_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105220","article-title":"Insufficient immunity led to virologic breakthrough in NAs-treated chronic hepatitis B patients switching to Peg-IFN-\u0251","volume":"197","author":"Huang","year":"2022","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2023.100751_bib23","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100751_bib24","article-title":"Interferon-based treatment of chronic hepatitis","author":"Sandmann","year":"2022","journal-title":"D\u00a0Liver Int"},{"key":"10.1016\/j.jhepr.2023.100751_bib25","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100751_bib26","first-page":"S26","article-title":"Bulevirtide, with or without peg-interferon, in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program","volume":"76","author":"De L\u00e9dinghen","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100751_bib27","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3390\/cells11223531","article-title":"Treatment of chronic hepatitis D with bulevirtide \u2013 a fight against two foes \u2013 an update","volume":"11","author":"Ferenci","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jhepr.2023.100751_bib28","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/hep.32732","article-title":"Clinical trials in hepatitis D virus: measuring success","volume":"77","author":"Da","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100751_bib29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/liv.14740","article-title":"Residual low HDV viraemia is associated HDV RNA relapse after PegIFNa-based antiviral treatment of hepatitis delta: results from the HIDIT-II study","volume":"41","author":"Bremer","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2023.100751_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2021.104932","article-title":"Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: a European multicenter study","volume":"142","author":"Stelzl","year":"2021","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jhepr.2023.100751_bib31","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/liv.14950","article-title":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life","volume":"41","author":"Asselah","year":"2021","journal-title":"Liver Int"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923000824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923000824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:30:32Z","timestamp":1762900232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923000824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2589555923000824"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100751","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100751"}}